Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Forest Memantine Plans Include Expanded Mild Alzheimer’s Indication

Executive Summary

Forest plans to expand the indication of its Alzheimer's drug Namenda (memantine) to include patients with mild dementia if study results expected at the end of the year are positive
Advertisement

Related Content

Forest Namenda Clears FDA; Alzheimer Drug Shipments To Begin In December
Forest Memantine Shows Small But Consistent Effect In Alzheimer’s – Cmte.
Forest Lexapro Strategy Changes: Reps Encouraging Switches From Celexa
Forest Lexapro Strategy Changes: Reps Encouraging Switches From Celexa
Advertisement
UsernamePublicRestriction

Register

PS042570

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel